Your browser doesn't support javascript.
loading
Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands.
Blommestein, Hedwig M; de Groot, Saskia; Aarts, Mieke J; Vemer, Pepijn; de Vries, Robin; van Abeelen, Annet F M; Posthuma, E F M Ward; Uyl-de Groot, Carin A.
Afiliação
  • Blommestein HM; Institute for Medical Technology Assessment, Institute of Health Policy and Management, Erasmus University Rotterdam, The Netherlands; Netherlands Comprehensive Cancer Organisation, Netherlands Cancer Registry Utrecht, The Netherlands. Electronic address: blommestein@bmg.eur.nl.
  • de Groot S; Institute for Medical Technology Assessment, Institute of Health Policy and Management, Erasmus University Rotterdam, The Netherlands.
  • Aarts MJ; Netherlands Comprehensive Cancer Organisation, Netherlands Cancer Registry Utrecht, The Netherlands.
  • Vemer P; University of Groningen, Pharmacotherapy, -Epidemiology, -Economics (PTE2), Groningen, The Netherlands; University of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen, The Netherlands.
  • de Vries R; Roche Nederland B.V., Health Economics and Business Development, Woerden, The Netherlands.
  • van Abeelen AF; Roche Nederland B.V., Health Economics and Business Development, Woerden, The Netherlands.
  • Posthuma EF; Department of Internal Medicine, Reinier de Graaf Group, Delft, The Netherlands.
  • Uyl-de Groot CA; Institute for Medical Technology Assessment, Institute of Health Policy and Management, Erasmus University Rotterdam, The Netherlands; Netherlands Comprehensive Cancer Organisation, Netherlands Cancer Registry Utrecht, The Netherlands.
Leuk Res ; 50: 37-45, 2016 11.
Article em En | MEDLINE | ID: mdl-27657652
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Análise Custo-Benefício / Anticorpos Monoclonais Humanizados Tipo de estudo: Health_economic_evaluation Aspecto: Patient_preference Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Leuk Res Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Análise Custo-Benefício / Anticorpos Monoclonais Humanizados Tipo de estudo: Health_economic_evaluation Aspecto: Patient_preference Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Leuk Res Ano de publicação: 2016 Tipo de documento: Article